Danusertib

Drug Profile

Danusertib

Alternative Names: NMS Aurora inhibitor; PHA-739358

Latest Information Update: 27 Jul 2015

Price : $50

At a glance

  • Originator Nerviano Medical Sciences
  • Developer National Cancer Institute (USA); Nerviano Medical Sciences
  • Class Antineoplastics; Benzamides; Pyrazoles; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myeloid leukaemia; Prostate cancer; Solid tumours
  • Phase I Acute lymphoblastic leukaemia
  • Discontinued Multiple myeloma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 27 Jul 2015 Clinical development of danusertib is ongoing for Solid tumours and Haematological malignancies
  • 06 Jun 2011 Final adverse events and efficacy data from a phase II trial in Prostate cancer presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top